Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies
Under the deal, Quiver will receive an undisclosed advance payment and research support
Under the deal, Quiver will receive an undisclosed advance payment and research support
Applications include detailed scientific rationale and supporting clinical evidence
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
Subscribe To Our Newsletter & Stay Updated